Dermatology researchers in the US have developed an artificial intelligence program that uses histology samples to identify which patients with melanoma will respond to immunotherapy. They say the system offers a better performance than genomic biomarkers such as PD-L1, which may be modified during the course of immune checkpoint inhibitor therapy. Instead, their machine learning ...
Artificial Intelligence program uses melanoma histology to guide immunotherapy
By Michael Woodhead
27 Nov 2020